Orbactiv sales history revenue
WebORBACTIV is contraindicated in patients with known hypersensitivity to ORBACTIV. 5 WARNINGS AND PRECAUTIONS 5.1 Coagulation Test Interference . ORBACTIV has been shown to artificially prolong aPTT for up to 120 hours, PT and INR for up to 12 hours, and activated clotting time (ACT) for up to 24 hours following administration of a WebOrbactiv Sales Medicare Prescription Data PharmaCompass.com. Filters. Reset Filter. Price Info. Product Main Page. U.S. MEDICAID PRESCRIPTIONS. Upload your Marketing & …
Orbactiv sales history revenue
Did you know?
WebTable 1: Orbactiv, Description Table 2: Product Details Table 3: Orbactiv, Historical Sales till 2024 (in million USD) Table 4: Orbactiv, Forecasted Sales from 2024-2024 (in million USD) … WebNov 11, 2014 · On August 6, 2014, the FDA announced approval of Orbactiv (oritavancin) injection for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by species of Streptococci, Enterococcus faecalis, and Staphylococcus aureus, including methicillin-resistant strains of Staphylococcus aureus. 1,2
WebORBACTIV® (oritavancin) for injection J code is J2407 injection, oritavancin, 10 mg. Reimbursement Guide Executive Summary Sample Billing Forms Revised Q1 2024 … WebSales Leadership & Product Market Growth - Increased Orbactiv utilization by 270 units in 2016 verses 2015 for an increase of $783k and total Orbactiv sales revenue of $2.1 million;...
WebSales history aids analysts in determining current sales trends and identifying patterns of buying behaviour or revenue cycles. One or more of the following can be used to identify these trends: 1. The kind of product 2. Sales territory 3. The time of year 4. Customer groups (by gender, age, occupation, and so on) WebFacilitating access to Orbactiv® (oritavancin) for your patients. 1-844-ORBACTIV (1-844-672-2284) Monday - Friday, 8:00 AM - 8:00 PM ET or email us. Medical Information. For medical inquiries or to report an adverse event, other safety related information, or product complaints for a company product, please contact Medical Information. ...
WebORBACTIV® (oritavancin): The first. Single dose. regimen for treating ABSSSI. A single 1200 mg infusion helps ensure adherence to a full course of therapy. * Mild renal impairment creatine clearance (CrCl) 50-79 mL/min, moderate renal impairment CrCl 30-49 mL/min. † Moderate hepatic impairment (Child-Pugh Class B).
Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin. The U.S. Food and Drug Administration (FDA) and … See more Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It … See more Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as See more Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in … See more In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) caused by Gram-positive bacteria. The primary endpoints of … See more • "Oritavancin". Drug Information Portal. U.S. National Library of Medicine. See more foam chemical nameWebFeb 25, 2024 · ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1,200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg vials. greenwich now galleryWebORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureu s (including methicillin-susceptible [MSSA] and -resistant [MRSA ... greenwich nsw real estateWebFeb 22, 2024 · Orbactiv (oritavancin) for injection is an antibiotic used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram -positive microorganisms: Staphylococcus aureus (including methicillin -susceptible and methicillin-resistant isolates), Streptococcus pyogenes, … greenwich nursery managerWebFeb 22, 2024 · Orbactiv IV is a prescription medicine used to treat the symptoms of Acute Bacterial Skin and Skin Structure Infections. Orbactiv IV may be used alone or with other medications. Orbactiv IV belongs to a class of drugs called Glycopeptides. It is not known if Orbactiv IV is safe and effective in children younger than 18 years of age. greenwich nsw councilWebORBACTIV® is contraindicated in patients with known hypersensitivity to oritavancin products. Warnings and Precautions Coagulation test interference: Oritavancin has been … foam chemical machine rentalsWebAug 7, 2014 · ORBACTIV approval is based on the results of the SOLO I and SOLO II clinical studies which were randomized, double-blind, multicenter trials that evaluated a single 1200 mg IV dose of ORBACTIV for ... foam chemical guys